Case study: Epicyte Pharmaceutical

Biopharming a Rich Harvest

By targeting an Associated Press reporter, the client received international coverage on news services and major daily newspapers in additional the biotechnology and IP trade press.

Epicyte Pharmaceutical announced the issuance of a patent for a technology that could lead to production of promising new treatments for infectious and inflammatory diseases not addressed by current therapies. To obtain coverage by the mainstream news media, the agency a primary target: a West Coast-based biotechnology writer for the Associated Press. He ran with it and the announcement received broad pick-up across the country.

While the story could have been confined to BIOTECH Patent News (where it did run) and the usual biotech trade suspects, the agency’s strategic pitch secured coverage in several mainstream targets, including The Los Angeles Times, The San Diego-Union Tribune, The Independent on Sunday (London), Copley News Service and Bloomberg News, among others. These results achieved the goal of creating broader awareness and understanding of Epicyte as it pursued subsequent rounds of financing as it ramped up toward an initial public offering (IPO).